CN100528222C - 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途 - Google Patents

共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途 Download PDF

Info

Publication number
CN100528222C
CN100528222C CNB988031221A CN98803122A CN100528222C CN 100528222 C CN100528222 C CN 100528222C CN B988031221 A CNB988031221 A CN B988031221A CN 98803122 A CN98803122 A CN 98803122A CN 100528222 C CN100528222 C CN 100528222C
Authority
CN
China
Prior art keywords
copolymer
fed
eae
cells
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988031221A
Other languages
English (en)
Chinese (zh)
Other versions
CN1249690A (zh
Inventor
R·阿农
M·瑟拉
D·泰特鲍姆
A·吉尔伯特
M·利南伯格
R·里文-克雷特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN1249690A publication Critical patent/CN1249690A/zh
Application granted granted Critical
Publication of CN100528222C publication Critical patent/CN100528222C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
CNB988031221A 1997-01-10 1998-01-12 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途 Expired - Lifetime CN100528222C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
IL119989 1997-01-10

Publications (2)

Publication Number Publication Date
CN1249690A CN1249690A (zh) 2000-04-05
CN100528222C true CN100528222C (zh) 2009-08-19

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988031221A Expired - Lifetime CN100528222C (zh) 1997-01-10 1998-01-12 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途

Country Status (18)

Country Link
EP (1) EP0975351B1 (https=)
JP (1) JP4216342B2 (https=)
KR (1) KR20000070058A (https=)
CN (1) CN100528222C (https=)
AT (1) ATE356608T1 (https=)
AU (1) AU737287B2 (https=)
BR (1) BRPI9807076B8 (https=)
CA (1) CA2277365C (https=)
CZ (1) CZ297983B6 (https=)
DE (1) DE69837324T2 (https=)
EA (1) EA003128B1 (https=)
HU (1) HU226612B1 (https=)
IL (2) IL119989A0 (https=)
NZ (1) NZ336690A (https=)
PL (1) PL193300B1 (https=)
SK (1) SK284029B6 (https=)
WO (1) WO1998030227A1 (https=)
ZA (1) ZA98214B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
WO2000005249A2 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
JP2003522121A (ja) * 1999-06-04 2003-07-22 フェレニヒング フォール クリステレイク ウェテンスハッペリキク オンデルウェイス 多発性硬化症の処置のためのリルゾールの使用
IL150895A0 (en) * 2000-02-18 2003-02-12 Teva Pharma Oral, nasal and pulmonary formulations of copolymer-1
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0302333A3 (en) * 2000-06-05 2005-07-28 Teva Pharma The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
DK1485127T3 (da) 2002-02-25 2011-10-03 Elan Pharm Inc Anvendelse af midler til behandling af inflammation
CA2514117A1 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649538B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
NZ336690A (en) 2001-05-25
SK93199A3 (en) 2000-11-07
WO1998030227A1 (en) 1998-07-16
AU5819598A (en) 1998-08-03
PL193300B1 (pl) 2007-01-31
EP0975351A1 (en) 2000-02-02
EP0975351B1 (en) 2007-03-14
EA199900621A1 (ru) 2000-02-28
HUP0001917A3 (en) 2001-12-28
BR9807076A (pt) 2000-05-02
HU226612B1 (en) 2009-04-28
DE69837324D1 (de) 2007-04-26
KR20000070058A (ko) 2000-11-25
ATE356608T1 (de) 2007-04-15
HUP0001917A2 (hu) 2000-10-28
JP2001511121A (ja) 2001-08-07
SK284029B6 (sk) 2004-08-03
PL334566A1 (en) 2000-03-13
BR9807076B1 (pt) 2013-10-29
EP0975351A4 (en) 2002-05-15
CZ243799A3 (cs) 2000-06-14
AU737287B2 (en) 2001-08-16
IL119989A0 (en) 1997-04-15
BRPI9807076B8 (pt) 2021-05-25
ZA98214B (en) 1999-08-11
CN1249690A (zh) 2000-04-05
IL130820A (en) 2007-03-08
HK1025737A1 (en) 2000-11-24
JP4216342B2 (ja) 2009-01-28
EA003128B1 (ru) 2003-02-27
CZ297983B6 (cs) 2007-05-16
CA2277365C (en) 2011-04-12
CA2277365A1 (en) 1998-07-16
DE69837324T2 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
CN100528222C (zh) 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途
US6214791B1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1998030227A9 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
AU742970B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
KR100239743B1 (ko) 인슐린을 함유하는 타입 1 당뇨병 치료용 경구투여, 장내투여 또는 흡입경구투여용 제제
JP3712260B2 (ja) 自己免疫疾患のバイスタンダー抑制
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
JP2002503658A (ja) ＣＯＰ−１及びＴｈ−２促進性サイトカインを使用した、多発性硬化症の治療
JP3183378B2 (ja) ムチン産生促進剤
HK1025737B (en) Treatment of multiple sclerosis through ingestion of copolymer-1
MXPA99006457A (en) Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1
AU781126B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
WO2025160184A1 (en) Methods for the prophylaxis and treatment of obesity and related conditions and disorders
CN118121583A (zh) 赖氨酸在制备治疗多发性硬化症药物中的应用
CN1353616A (zh) 一种物质在pns中的新用途

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20090819

CX01 Expiry of patent term